Cancer Cytokines Therapy Pipeline Analysis

Publish Date:- Jun-2014       No Of Pages (165)

Electronic Access - Single User License $1800 Buy Now
CD-ROM Mail Delivery $2100Buy Now
Hard Copy Mail Delivery $2400 Buy Now
Electronic Access - Multi-User License $3600 Buy Now


Cytokines, a major group in the protein therapeutics umbrella, are known to be soluble extracellular proteins or glycoproteins which are crucial intercellular regulators, having the capacity to mobilize the cells which are engaged in innate as well as adaptive inflammatory host defenses, cell growth, differentiation, cell death, angiogenesis, and development and repair processes aimed at the restoration of homeostasis. These proteins are being used mostly for cancer patients due to their capability to stop tumor growth. Cytokines are considered to be a large, diverse group of extracellular proteins which are produced by the immune system cells. These cytokines have the capacity to be bound by the cytokine receptors on the targeted cells. This process initiates a signaling cascade within those cells.

The growth in the cytokines market is mainly driven by its increased application for cancer treating methods, along with an increased spending on research and development, advances in technology, patent expiries, and rising competition. Cytokines are related to almost all the therapeutic protein drug development processes. The cytokine and growth factor related products include antibodies, proteins and nucleic acid probes which are being extensively used in a wide variety of applications from the basic research laboratory through the drug discovery process, to in vivo therapeutic use. The companies producing these proteins are focusing their strategy on offering high quality products at more than competitive prices.

It is expected that in the next 4-5 years, the pharma companies would focus more on the development of successful cancer therapies based on cytokines. The allocation of resources should necessarily reflect ongoing, strategic prioritization of candidates in the pipeline. With the progress of trials and accumulation of information on the safety and efficacy of new cytokines products, there is an urgent demand for strategizing the product pipelines and the prioritization of the decisions. This segment has proved to be the most important investment to control the sprawling rise in cancer incidence rates. Also, from a commercial viewpoint, these cytokine products are likely to churn significant revenues and for the patient population, and eventually are expected to improve the survival rates and improve quality of life.


Cancer Cytokines Therapy Pipeline Analysis” Report Highlights:

• Cancer Cytokines Therapy Market Overview
• Marketed Drug Profiles & Patent Analysis
• Clinical Trial Insight by Phase & Country
• Drug in Clinical Development Phase: 64
• Majority Therapies in Preclinical Phase: 25
• Marketed Cytokines Therapies: 15
• Suspended & Discontinued Drug Profiles: 67
• Competitive Landscape


Cytokines, a major group in the protein therapeutics umbrella, are known to be soluble extracellular proteins or glycoproteins which are crucial intercellular regulators, having the capacity to mobilize the cells which are engaged in innate as well as adaptive inflammatory host defenses, cell growth, differentiation, cell death, angiogenesis, and development and repair processes aimed at the restoration of homeostasis. These proteins are being used mostly for cancer patients due to their capability to stop tumor growth. Cytokines are considered to be a large, diverse group of extracellular proteins which are produced by the immune system cells. These cytokines have the capacity to be bound by the cytokine receptors on the targeted cells. This process initiates a signaling cascade within those cells.

The growth in the cytokines market is mainly driven by its increased application for cancer treating methods, along with an increased spending on research and development, advances in technology, patent expiries, and rising competition. Cytokines are related to almost all the therapeutic protein drug development processes. The cytokine and growth factor related products include antibodies, proteins and nucleic acid probes which are being extensively used in a wide variety of applications from the basic research laboratory through the drug discovery process, to in vivo therapeutic use. The companies producing these proteins are focusing their strategy on offering high quality products at more than competitive prices.

It is expected that in the next 4-5 years, the pharma companies would focus more on the development of successful cancer therapies based on cytokines. The allocation of resources should necessarily reflect ongoing, strategic prioritization of candidates in the pipeline. With the progress of trials and accumulation of information on the safety and efficacy of new cytokines products, there is an urgent demand for strategizing the product pipelines and the prioritization of the decisions. This segment has proved to be the most important investment to control the sprawling rise in cancer incidence rates. Also, from a commercial viewpoint, these cytokine products are likely to churn significant revenues and for the patient population, and eventually are expected to improve the survival rates and improve quality of life.


Cancer Cytokines Therapy Pipeline Analysis” Report Highlights:

• Cancer Cytokines Therapy Market Overview
• Marketed Drug Profiles & Patent Analysis
• Clinical Trial Insight by Phase & Country
• Drug in Clinical Development Phase: 64
• Majority Therapies in Preclinical Phase: 25
• Marketed Cytokines Therapies: 15
• Suspended & Discontinued Drug Profiles: 67
• Competitive Landscape

1. Cancer Cytokines Therapy Market Overview
  1.1 Market Overview
  1.2 Clinical Pipeline Insight

2. Cancer Cytokine Therapy Clinical Trial Insight by Phase, Country & Target Indications
  2.1 Unknown Phase
  2.2 Research
  2.3 Preclinical
  2.4 Clinical
  2.5 Phase I
  2.6 Phase I/II
  2.7 Phase II
  2.8 Phase III

3. Marketed Cancer Cytokines Clinical Profile & Patent Analysis

4. Suspended & Discontinued Cancer Cytokines Therapy in Clinical Trial
  4.1 No Development Reported
  4.2 Discontinued
  4.3 Suspended

5. Competitive Landscape
  5.1 Altor BioScience
  5.2 Biogenomics
  5.3 Biosidus
  5.4 Chiron Corporation (Novartis)
  5.5 Expression Genetics
  5.6 IRX Therapeutics
  5.7 Philogen
  5.8 Roche
  5.9 Regulon
  5.10 ZymoGenetics

Figure 1-1: Cancer Cytokines Therapy Clinical Pipeline by Phase (%), 2014
Figure 1-2: Cancer Cytokines Therapy Clinical Pipeline by Phase (Number), 2014
Figure 1-3: No Development in Cancer Cytokines Therapy Clinical Pipeline by Phase (%), 2014
Figure 1-4: No Development in Cancer Cytokines Therapy Clinical Pipeline by Phase (Number), 2014
Figure 1-5: Discontinued Cancer Cytokines Therapy Clinical Pipeline by Phase (%), 2014
Figure 1-6: Discontinued Cancer Cytokines Therapy Clinical Pipeline by Phase (Number), 2014
Figure 1-7: Suspended Cancer Cytokines Therapy Clinical Pipeline by Phase (%), 2014
Figure 1-8: Suspended Cancer Cytokines Therapy Clinical Pipeline by Phase (Number), 2014
Figure 5-1: Expression Genetics Clinical Pipeline
Figure 5-2: Philogen Clinical Pipeline

List of Tables


Following Information For Each Drug Profile in Covered in More than 200 Tables in Report:

• Drug Profile Overview
• Active Indication
• Phase of Development
• Country for Clinical Trial
• Owner / Originator/ Licensee/Collaborator
• Administrative Route
• Drug Class


Each Drug Profile has Tables Representing Following Information:

• Alternate Names

• Originator & Owner

• Collaborator

• Technology Provider

• Licensee

• Highest Development Phase

• Indications

• Class

• Mechanism of Action

• ATC Code

• Designated Brand Name